Navigating the therapeutic landscape: Biologics and immunosuppressive therapy in lupus nephritis during pregnancy. (PubMed, Lupus) - Jul 10, 2026 - "The therapeutic armamentarium for LN has expanded considerably with the approval of voclosporin, belimumab, and obinutuzumab, yet pregnancy safety data for these agents remain conspicuously absent...Key guidelines, pregnancy registries, and landmark clinical trial data were incorporated.ResultsHydroxychloroquine and azathioprine remain the cornerstones of pregnancy-compatible LN management...Low-dose aspirin is recommended universally to reduce preeclampsia risk. Mycophenolate mofetil is teratogenic and absolutely contraindicated in the first trimester...Rituximab may be used cautiously for life-threatening disease, avoiding the third trimester due to neonatal B-cell depletion. Anifrolumab has no pregnancy data and should be reserved for situations where no compatible alternative exists.ConclusionThe growing number of effective LN therapies creates both opportunities and new dilemmas in pregnancy management. A structured, phase-based approach to drug selection -..."
Journal • Review • Acute Kidney Injury • Glomerulonephritis • Gynecology • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|